Disposition of 750 shares by Dunbar George W Jr of Capricor Therapeutics at 1. subject to Rule 16b-3
| CAPR Stock | USD 7.63 0.05 0.65% |
Slightly above 56% of Capricor Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Capricor Therapeutics stock suggests that many investors are alarmed at this time. Capricor Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Capricor Therapeutics. Many technical investors use Capricor Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Filed transaction by Capricor Therapeutics Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Capricor Therapeutics Fundamental Analysis
We analyze Capricor Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Capricor Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Capricor Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Capricor Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Capricor Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Capricor Therapeutics stock to make a market-neutral strategy. Peer analysis of Capricor Therapeutics could also be used in its relative valuation, which is a method of valuing Capricor Therapeutics by comparing valuation metrics with similar companies.
Peers
Capricor Therapeutics Related Equities
| AYTU | Aytu BioScience | 10.42 | ||||
| CRVO | CervoMed | 5.36 | ||||
| CRNX | Crinetics Pharmaceuticals | 1.36 | ||||
| MBRX | Moleculin Biotech | 0.62 | ||||
| PULM | Pulmatrix | 1.29 |
Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.